US prescribing guidelines recommend that 15‐and 20‐mg doses of rivaroxaban be
administered with food for the treatment of deep vein thrombosis (DVT) and pulmonary …

Rivaroxaban (RRN) is the first available active direct factor Xa inhibitor (anticoagulant) with
oral administration. Due to its success in market, there have been efforts to develop various …

Purpose To enhance the oral bioavailability of revaprazan (RVP), a novel solid,
supersaturable micelle (SSuM) was developed. Methods Surfactants and solid carriers were …

The purpose of this work was to develop a sensitive and validated HPLC method for
analysis of rivaroxaban and estimation of related impurities in parent drug substance and …

ABSTRACT A simple, sensitive and reproducible method was developed on ultra
performance liquid chromatography (UPLC) coupled with a photodiode array detector for the …

Background The crushed-tablet rivaroxaban concentration has been previously reported to
be lower than the non-crushed concentration. However, the rivaroxaban concentration of …

Rivaroxaban (RN) is a recently developed potent oral anticoagulant. The aim of the present
study envisages compatibility studies of rivaroxaban with crospovidone, sodium startch …

Aim: To develop dabigatran etexilate (DE)-loaded self-nanoemulsifying drug delivery
systems (SNEDDS) for the prevention of stroke and thromboembolism. Materials & methods …

Rivaroxaban, an anti-clotting medication, acts at a crucial point in the blood-clotting process
and stops the formation of blood clots. In this study, RP-HPLC method was developed for the …

Phospholipid-based nanosystems show promising potentials for oral administration of
hydrophobic drugs. The study introduced a novel approach to optimize posaconazole …